老年弥漫大B细胞淋巴瘤诊断与治疗中国专家共识(2024年版)
Chinese expert consensus on the diagnosis and management of elderly patients with diffuse large B-cell lymphoma(2024)
中华医学会血液学分会淋巴细胞疾病学组 中国临床肿瘤学会(CSCO)淋巴瘤专家委员会 徐兵 1赵维莅 2马军3
作者信息
- 1. 厦门大学附属第一医院,厦门大学血液病学系,厦门市血液病质控中心,厦门市血液治疗精准诊治重点实验室,厦门 361003
- 2. 上海血液学研究所,医学基因组学国家重点实验室,转化医学国家重大科技基础设施(上海),上海交通大学医学院附属瑞金医院,上海 200025
- 3. 哈尔滨血液病肿瘤研究所,哈尔滨 150010
- 折叠
摘要
随着人口老龄化来临,老年弥漫大B细胞淋巴瘤(Diffuse large B cell lymphoma,DLBCL)患者比例上升.老年患者对治疗耐受性差,治疗方案需要个体化制定.为提高我国临床医师对老年DLBCL的诊断及治疗水平,中华医学会血液病学分会淋巴细胞疾病学组和中国临床肿瘤学会(CSCO)淋巴瘤专家委员会组织相关专家制定了本共识.
Abstract
The general population in China is aging,and thus the number of older patients with diffuse large B-cell lymphoma(DLBCL)will continue to increase.Individualized treatment is required to maximize therapeutic potential while minimizing the risk of toxicity.To improve the diagnosis and treatment of DLBCL in older people in China,the Lymphocyte Disease Group of the Hematology Division of the Chinese Medical Association and Lymphoma Expert Commitee of Chinese Society of Clinical Oncology(CSCO)have organized relevant experts to formulate this consensus.
关键词
淋巴瘤,大B细胞,弥漫性/老年/诊断/治疗Key words
Lymphoma,large B-cell,diffuse/Geriatric/Diagnosis/Therapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据